Literature DB >> 16799818

Plasma Hsp72 is higher in runners with more serious symptoms of exertional heat illness.

P A Ruell1, M W Thompson, K M Hoffman, J R Brotherhood, D A B Richards.   

Abstract

Exertional heat illness is a potentially fatal disorder that primarily affects fit young men. Plasma Hsp72 may be important in the aetiology of this disorder, acting as a danger signal to the organism and leading to an inflammatory response. The aim of this study was to determine whether patients with exertional heat illness following a 14 km run show a difference in their plasma Hsp72 concentration compared with control subjects who completed the event without incident. Patients (n = 22) and controls (n = 7) were all male. The patients were subdivided into two groups, one of which exhibited more serious symptoms indicating neurological impairment such as confusion (n = 13) (CNS) while the other group exhibited mild symptoms (MILD) (n = 9). The CNS group had a higher rectal temperature (T(rec)) compared with the control group (41.0 +/- 0.3 vs. 39.8 +/- 0.2 degrees C, P < 0.05, mean +/- SE). Immediately after the run plasma Hsp72 was higher in the CNS group compared to controls and patients with mild symptoms (37.9, 17.0, and 20.9 ng/ml, respectively, P < 0.005). There was a correlation between plasma Hsp72 and T(rec) measured immediately after the race (r = 0.597, P < 0.001, n = 29). However, core temperature was not the only factor leading to increased plasma Hsp72 immediately post race. Plasma Hsp72 was still higher in CNS patients compared with the control group (P < 0.05) when T(rec )was included as a covariate. In conclusion, plasma Hsp72 was elevated immediately after a 14 km run with higher levels in patients with more serious symptoms of heat illness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799818     DOI: 10.1007/s00421-006-0230-9

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  25 in total

Review 1.  Heat stroke.

Authors:  Abderrezak Bouchama; James P Knochel
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

2.  Hsp70 release from peripheral blood mononuclear cells.

Authors:  Claire Hunter-Lavin; Emma L Davies; Maria M F V G Bacelar; Michael J Marshall; Sarah M Andrew; John H H Williams
Journal:  Biochem Biophys Res Commun       Date:  2004-11-12       Impact factor: 3.575

3.  The medical problems of mass participation in athletic competition. The "City-to-Surf" race.

Authors:  J Sutton; M J Coleman; A P Millar; L Lazarus; P Russo
Journal:  Med J Aust       Date:  1972-07-15       Impact factor: 7.738

4.  Biochemical and haematological changes in Sydney's the Sun City-to-Surf fun runners.

Authors:  D Richards; R Richards; P J Schofield; V Ross
Journal:  Med J Aust       Date:  1979-11-03       Impact factor: 7.738

Review 5.  Hyperthermia.

Authors:  H B Simon
Journal:  N Engl J Med       Date:  1993-08-12       Impact factor: 91.245

6.  Effect of temperature and duration of hyperthermia on HSP72 induction in rat tissues.

Authors:  P A Ruell; K M Hoffman; C M Chow; M W Thompson
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

7.  Serum levels of Hsp 72 measured early after trauma correlate with survival.

Authors:  Jean-François Pittet; H Lee; Diane Morabito; M B Howard; William J Welch; Robert C Mackersie
Journal:  J Trauma       Date:  2002-04

8.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

9.  Inflammatory, hemostatic, and clinical changes in a baboon experimental model for heatstroke.

Authors:  A Bouchama; G Roberts; F Al Mohanna; R El-Sayed; B Lach; S Chollet-Martin; V Ollivier; R Al Baradei; A Loualich; S Nakeeb; A Eldali; D de Prost
Journal:  J Appl Physiol (1985)       Date:  2004-10-08

10.  Management of heat exhaustion in Sydney's the Sun City-to-Surf run runners.

Authors:  D Richards; R Richards; P J Schofield; V Ross; J R Sutton
Journal:  Med J Aust       Date:  1979-11-03       Impact factor: 7.738

View more
  7 in total

1.  The effect of the rate of heat storage on serum heat shock protein 72 in humans.

Authors:  Fabiano T Amorim; Paulette M Yamada; Robert A Robergs; Suzanne M Schneider; Pope L Moseley
Journal:  Eur J Appl Physiol       Date:  2008-08-14       Impact factor: 3.078

2.  Extracellular Hsp72 concentration relates to a minimum endogenous criteria during acute exercise-heat exposure.

Authors:  Oliver R Gibson; Alex Dennis; Tony Parfitt; Lee Taylor; Peter W Watt; Neil S Maxwell
Journal:  Cell Stress Chaperones       Date:  2013-10-02       Impact factor: 3.667

Review 3.  Pathophysiology of heatstroke in dogs - revisited.

Authors:  Yaron Bruchim; Michal Horowitz; Itamar Aroch
Journal:  Temperature (Austin)       Date:  2017-10-09

4.  A comparison of two commercially available ELISA methods for the quantification of human plasma heat shock protein 70 during rest and exercise stress.

Authors:  B J Lee; N M Sukri; H Ogden; C Vine; C D Thake; J E Turner; J L J Bilzon
Journal:  Cell Stress Chaperones       Date:  2015-06-26       Impact factor: 3.667

5.  Plasma Hsp72 (HSPA1A) and Hsp27 (HSPB1) expression under heat stress: influence of exercise intensity.

Authors:  Julien D Périard; Patricia Ruell; Corinne Caillaud; Martin W Thompson
Journal:  Cell Stress Chaperones       Date:  2012-01-06       Impact factor: 3.667

6.  Toward establishment of temperature thresholds for immunological impact of heat exposure in humans.

Authors:  Sarah H Beachy; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

Review 7.  Heat shock protein 72 response to exercise in humans.

Authors:  Paulette Yamada; Fabiano Amorim; Pope Moseley; Suzanne Schneider
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.